Significant Rise in the Prevalence of Chronic Diseases is Driving Asia-Pacific Biologics Market

Asia-Pacific biologics market is estimated to grow at a CAGR of 9.2% during the forecast period. A significant rise in the prevalence of chronic diseases is reflecting positively on the market growth. An increasing prevalence of chronic diseases such as cancer and autoimmune diseases are some crucial factors accelerating market growth. The rising geriatric population is one of the major causes for the rising incidences of autoimmune diseases in the region. As per the United Nations Economic and Social Commission for Asia and the Pacific, the number of older persons expected to more than double, from 535 million in 2015 to nearly 1.3 billion in 2050. 

Browse the full report description of "Asia-Pacific Biologics Market Size, Share & Trends Analysis Report, By Product (Antibody Therapeutics, Vaccines, Cell Therapy, Gene Therapy, and Others), By Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/asia-pacific-biologics-market

This results in an increasing demand for biologics for the treatment of autoimmune diseases, including rheumatoid arthritis. Biologics drugs function by disrupting the inflammation process that results in joint pain and destruction. These are genetically engineered drugs that are intended to interact with the immune response to reduce the damaging effects of rheumatologic disorders. For rheumatoid arthritis, these drugs particularly target proteins that are involved in joint inflammation. In some rheumatoid arthritis patients, biologics can be provided alone or along with traditional drugs to support slowing down the progression of rheumatoid arthritis. 

Scope of the Asia-Pacific Biologics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Product and Application
• Countries Covered- China, India, Japan, and Rest of Asia-Pacific
• Competitive Landscape- AbbVie Inc., Eli Lilly and Co., F. Hoffman-La Roche AG, and Daiichi Sankyo Co., Ltd.

Recent Strategic Initiatives in the Asia-Pacific Biologics Market

• In November 2019, China’s Bio-Thera Solutions Ltd. gained regulatory approval for its AbbVie Inc’s blockbuster rheumatoid arthritis therapy Humira, which paves the way for the first such biosimilar to enter the world’s second-largest drug market. It has been approved to treat three autoimmune diseases, which include plaque psoriasis, rheumatoid arthritis, and ankylosing spondylitis. The approval of this drug will offer a new affordable treatment alternative for patients in China suffering from several kinds of autoimmune diseases. 
• In April 2019, Intas Pharmaceuticals declared the introduction of a ‘similar biologic’ of trastuzumab named Eleftha in India. This new drug claims that it will reduce the cost of breast cancer therapy by approximately 65%. It is a similar biologic of Herceptin (trastuzumab), Roche’s blockbuster breast cancer drug approved by the US FDA in September 1998 and by the European Medicines Agency (EMA) in August 2000. Herceptin is aimed to treat breast and gastric cancers.

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Asia-Pacific Biologics Market-Segmentation

By Product

• Antibody Therapeutics
• Vaccines
• Cell Therapy
• Gene Therapy
• Others

By Application

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

Asia-Pacific Biologics Market– Segment by Country

• China
• India
• Japan
• Rest of Asia-Pacific

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-biologics-market